Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

27.16 -0.98 (-3.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Is Moderna a Bad-News Buy for 2025?
Via The Motley Fool
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Via The Motley Fool
Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
 
Via Benzinga
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
Via The Motley Fool
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?
Traders adopted a cautious approach on Monday as they awaited two critical inflation reports due later this week, seeking clarity on Federal Reserve interest rate policy. 
Via Benzinga
Topics Economy
Moderna Stock Takes A 20% Hit
Moderna stock is now down close to 30% versus its YTD high. 
Via Talk Markets
Topics Stocks / Equities
Why Moderna Stock Just Crashed 21%
Via The Motley Fool
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
 
Via Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
 
Via Benzinga
Moderna Stock Sinks To Over 5-Year Low On $1B Sales Guidance Cut: Retail’s Shaken
The revised projection largely reflects declining COVID-19 vaccine demand, as fewer people seek boosters amid the ongoing shift to an endemic phase. 
Via Stocktwits
Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance
The company also had a setback for its CMV vaccine. 
Via Investor's Business Daily
Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
Moderna targets ten product approvals by 2027 while cutting R&D costs by $1.1 billion. FY2024 revenue reached $3 billion-$3.1 billion, with $9.5B in cash reserves. 
Via Benzinga
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
Spotlight on Moderna: Analyzing the Surge in Options Activity
 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
MarketBeat Week in Review – 01/06 - 01/10
Stocks continued to slide after a hot jobs report sent bond yields higher, lowered expectations for future rate cuts, and keeps inflation and earnings in focus 
Via MarketBeat
Topics Bonds Economy Government
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top ten worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
"Motley Fool Money" 2025 Stock Market Preview
New year, new market? Motley Fool analysts preview what's in store for investors in 2025, the companies they're excited to watch and the businesses they're worried about. 
Via The Motley Fool
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
Moderna Shares Spike on H5N1 News—What’s Next for Investors?
MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025 
Via MarketBeat
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Via The Motley Fool
Nvidia, Palantir, Ionq, Novavax, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced a downturn on Tuesday, with the Nasdaq Composite falling by 1.9% and the S&P 500 dropping by 1.1%.. 
Via Benzinga
Topics Stocks
Stocks Sink As Bond Yields Soar, Nvidia Eyes Worst Day In 4 Months, Bitcoin Tumbles To $97,000: What's Driving Markets Tuesday?
Tuesday began as a calm day on Wall Street, but markets swiftly turned negative after the Institute for Supply Management released data highlighting an unexpected surge in price pressures within the... 
Via Benzinga
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike
Moderna, BioNTech and Novavax stocks popped after the CDC noted a recent increase in positive Covid tests. 
Via Investor's Business Daily
S&P 500, Nasdaq Fall As Economic Data, Bond Yields Weigh
Stocks are mostly lower today, with the S&P 500 Index and Nasdaq Composite Index erasing early-morning gains. 
Via Talk Markets
Topics Stocks Stocks / Equities
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses... 
Via Benzinga
UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Investors Look Back at 2024
The S&P 500 had a great year. 
Via The Motley Fool
Topics Stocks
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.